Euro-Med Laboratories Philippines (PHS:EURO) EBIT: ₱947 Mil (TTM As of Mar. 2026)


PHS:EURO Euro-Med Laboratories Philippines Inc PHS:EURO
84 GF Score
Price ₱1.08
GF Value ₱1.02
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Euro-Med Laboratories Philippines EBIT?

Euro-Med Laboratories Philippines PHS:EURO 84 EBIT is ₱947 Mil as of Mar. 2026. GuruFocus rates PHS:EURO with a GF Score™ of 84/100 and a GF Value™ of ₱1.02 (Fairly Valued). The stock has 6 warning signs investors should review.

Euro-Med Laboratories Philippines's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₱184 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₱947 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Euro-Med Laboratories Philippines's annualized ROC % for the quarter that ended in Mar. 2026 was 5.98%. Euro-Med Laboratories Philippines's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 8.97%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Euro-Med Laboratories Philippines's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 13.75%.

Euro-Med Laboratories Philippines  (PHS:EURO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Euro-Med Laboratories Philippines's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=723.628 * ( 1 - 25.09% )/( (9196.396 + 8933.146)/ 2 )
=542.0697348/9064.771
=5.98 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=11144.61 - 421.76 - ( 1526.454 - max(0, 3832.621 - 5623.064+1526.454))
=9196.396

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=11110.34 - 471.262 - ( 1705.932 - max(0, 3754.351 - 5579.675+1705.932))
=8933.146

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Euro-Med Laboratories Philippines's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=735.316/( ( (4846.537 + max(3499.865, 0)) + (4826.782 + max(3229.548, 0)) )/ 2 )
=735.316/( ( 8346.402 + 8056.33 )/ 2 )
=735.316/8201.366
=8.97 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1841.145 + 1582.437 + 559.188) - (421.76 + 0 + 61.145)
=3499.865

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1838.462 + 1456.176 + 454.631) - (471.262 + 0 + 48.459)
=3229.548

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Euro-Med Laboratories Philippines's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=947.133/6890.329
=13.75 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Euro-Med Laboratories Philippines EBIT Related Terms

Euro-Med Laboratories Philippines EBIT Historical Data

* Premium members only.

The historical data trend for Euro-Med Laboratories Philippines's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Euro-Med Laboratories Philippines EBIT Chart

Euro-Med Laboratories Philippines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 446.17 488.58 672.29 746.43 940.87

Euro-Med Laboratories Philippines Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 165.45 195.47 243.61 324.22 183.83

PHS:EURO vs ZTS, UTHR, VTRS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Euro-Med Laboratories Philippines's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Euro-Med Laboratories Philippines EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Euro-Med Laboratories Philippines's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Euro-Med Laboratories Philippines's EV-to-EBIT falls into.


PHS:EURO
84GF Score
Euro-Med Laboratories Philippines Inc PHS:EURO
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Euro-Med Laboratories Philippines EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₱947 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₱947 Mil mean?
Euro-Med Laboratories Philippines (PHS:EURO) has a EBIT of ₱947 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Euro-Med Laboratories Philippines.
Is Euro-Med Laboratories Philippines' EBIT too high?
Euro-Med Laboratories Philippines' current EBIT is ₱947 Mil. Overall, Euro-Med Laboratories Philippines has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Euro-Med Laboratories Philippines' EBIT compare to ZTS and UTHR?
Euro-Med Laboratories Philippines' EBIT of ₱947 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Euro-Med Laboratories Philippines. Euro-Med Laboratories Philippines's current EBIT is ₱947 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Euro-Med Laboratories Philippines stock overvalued right now?
Based on GuruFocus' analysis, Euro-Med Laboratories Philippines (PHS:EURO) is currently considered Fairly Valued. The stock's GF Value™ is ₱1.02, compared to a current price of ₱1.08 — trading 5.9% above its estimated fair value. The current EBIT is ₱947 Mil. Euro-Med Laboratories Philippines' overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Euro-Med Laboratories Philippines (PHS:EURO), the current EBIT is ₱947 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Euro-Med Laboratories Philippines (PHS:EURO) Overvalued in 2026?

Based on GuruFocus' analysis, Euro-Med Laboratories Philippines stock appears to be overvalued. The current stock price of ₱1.08 is trading 5.9% above its estimated GF Value™ of ₱1.02. GuruFocus considers Euro-Med Laboratories Philippines to be Fairly Valued.

Key valuation signals for PHS:EURO:

  • EBIT: ₱947 Mil
  • GF Value™: ₱1.02 vs. price of ₱1.08 (5.9% above fair value)
  • GF Score™: 84/100 with 6 warning signs

No single metric tells the full story. See the PHS:EURO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Euro-Med Laboratories Philippines Business Description

Address San Marcelino Street, United Nations Avenue corner, PPL Building, 2nd floor, Manila, PHL, 1000
Euro-Med Laboratories Philippines Inc is a pharmaceutical-based company that engages in the manufacture of pharmaceutical products such as large and small-volume parenterals and other solutions. The company also manufactures sterile water for injection, and other solutions such as ophthalmic, inhalation, irrigation, and dialysis. The Company also manufactures intravenous fluids in glass bottles, hemodialysis concentrates, ophthalmic products and disinfectants.
84GF Score

Get the complete analysis for PHS:EURO

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₱1.08
Price
₱1.02
GF Value